Fresenius appoints Marc-Alexander Mahl. Fresenius stock sits 14.22 percent below its 52-week high.

Published on 10/23/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 45.43 on October 23, 2026, versus the Xetra close of EUR 45.30.

Corporate moves shape the outlook

On October 15, 2026, Fresenius appointed Marc-Alexander Mahl to its management board.
The mAbxience transaction covers the remaining 45 percent for up to EUR 750 million.
Fresenius stock trades at EUR 45.43 at 10:11 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.29 percent above the Xetra close of October 22, 2026 at EUR 45.30.
Fresenius is scheduled to publish its third-quarter 2026 report on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 45.43 at Lang & Schwarz on October 23, 2026 at 10:11 a.m. CEST, 0.29 percent above the Xetra close of October 22, 2026. The supervisory board appointed Marc-Alexander Mahl to the Fresenius Management Board and extended Sara Hennicken's contract, EQS News reported on October 15, 2026.

The modest daily move leaves the stock 14.22 percent below its EUR 52.96 52-week high. The same-day quote places the shares within a EUR 35.11 to EUR 52.96 52-week range.

Ownership strengthens the biopharma platform

Fresenius acquired the remaining 45 percent of mAbxience for total consideration of up to EUR 750 million, including a conditional EUR 50 million payment. The transaction was signed and completed on September 30, 2026, and gives Fresenius full ownership of the biosimilars platform, according to EQS News.

Fresenius said the acquisition should contribute immediately to adjusted earnings per share. mAbxience generated more than EUR 320 million in revenue in fiscal year 2025 and operates three production facilities with more than 1,300 employees.

What does the Q2 growth show?

Fresenius reported EUR 5.864 billion in revenue for the second quarter of 2026, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025. Core net income rose 14.00 percent to EUR 470 million, while core earnings per share increased 14.00 percent to EUR 0.83, according to the company's Investor Relations page.

The company also raised its full-year 2026 core earnings-per-share growth guidance to 10.00 percent to 15.00 percent at constant currency, from 5.00 percent to 10.00 percent. That guidance gives the November report a clear test: whether the first-half improvement is continuing into the third quarter.

Three dates frame the story

On September 7, 2026, Fresenius sold 7.8 million Fresenius Medical Care shares for about EUR 300 million. On October 1, 2026, it announced the EUR 750 million mAbxience transaction. On October 15, 2026, the supervisory board announced one management-board appointment and a contract extension, all listed in the EQS News chronology.

Upcoming reporting date

Fresenius is scheduled to publish its third-quarter 2026 financial report on November 4, 2026, according to its investor-relations calendar. Jefferies kept a Buy rating and a EUR 55.00 price target in a note dated October 20, 2026, as reported by finanzen.at.

Stock price and valuation context

Fresenius has a market capitalization of EUR 25.6 billion as of October 23, 2026. For investors, the combination of a 6.00 percent quarterly revenue increase, higher earnings guidance and the upcoming report date provides the clearest near-term framework for reading the stock.

The stock was trading at EUR 45.43 at Lang & Schwarz on October 23, 2026 at 10:11 a.m. CEST, 0.29 percent above the Xetra close of October 22, 2026 at EUR 45.30. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.